Search Results

You are looking at 1 - 8 of 8 items for :

  • "Prader–Willi syndrome" x
Clear All
Open access

A C Paepegaey, M Coupaye, A Jaziri, F Ménesguen, B Dubern, M Polak, J M Oppert, M Tauber, G Pinto and C Poitou

Introduction Prader–Willi syndrome (PWS) is a complex developmental genetic disorder including obesity with hyperphagia, psychiatric disturbances, endocrine and metabolic disorders ( 1 , 2 ). Global incidence has been recently evaluated as 1

Open access

Devis Pascut, Sofia Tamini, Silvia Bresolin, Pablo Giraudi, Giuseppe Basso, Alessandro Minocci, Claudio Tiribelli, Graziano Grugni and Alessandro Sartorio

Introduction Prader–Willi syndrome (PWS) is a complex multisystem disorder due to the lack of expression of genes located on the paternal chromosome 15q11.2-q13. Together with Angelman syndrome, a totally different clinical condition, PWS is

Open access

Anita Hokken-Koelega, Aart-Jan van der Lely, Berthold Hauffa, Gabriele Häusler, Gudmundur Johannsson, Mohamad Maghnie, Jesús Argente, Jean DeSchepper, Helena Gleeson, John W Gregory, Charlotte Höybye, Fahrettin Keleştimur, Anton Luger, Hermann L Müller, Sebastian Neggers, Vera Popovic-Brkic, Eleonora Porcu, Lars Sävendahl, Stephen Shalet, Bessie Spiliotis and Maithé Tauber

deficiency (CO-GHD), those born small for gestational age (SGA), girls with Turner syndrome (TS), patients with Prader–Willi syndrome (PWS), and survivors of cancers treated during childhood was addressed and, specifically, the role for GH therapy in patients

Open access

Metin Guclu, Sinem Kiyici, Zulfiye Gul and Sinan Cavun

also remained low for up to 8 h following exenatide administration. Prader–Willi syndrome (PWS) is associated with hyperphagia and obesity. Patients with PWS have high circulating ghrelin levels that do not decrease postprandially ( 23 ). There are

Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society

being treated with GH for non-GHD conditions, the change in height velocity or height SDS is used as surrogate endpoints. In patients with Prader–Willi syndrome, although auxological measures are important, measures of the metabolic actions of GH are

Open access

Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty and Wouter W de Herder

Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome . Endocrine 2015 50 633 – 642 . ( doi:10.1007/s12020-015-0614-x ) 32 Rindi G Kloppel G Alhman H Caplin M

Open access

Kristin Godang, Karolina Lundstam, Charlotte Mollerup, Stine Lyngvi Fougner, Ylva Pernow, Jörgen Nordenström, Thord Rosén, Svante Jansson, Mikael Hellström, Jens Bollerslev, Ansgar Heck and the SIPH Study Group

adult patients with Prader-Willi syndrome during treatment with growth hormone . Journal of Clinical Endocrinology and Metabolism 2014 99 E1727 – E1731 . ( https://doi.org/10.1210/jc.2014-2059 ) 10.1210/jc.2014-2059) 18 Bollerslev J Jansson S

Open access

Werner F Blum, Abdullah Alherbish, Afaf Alsagheir, Ahmed El Awwa, Walid Kaplan, Ekaterina Koledova and Martin O Savage

(very rare) GH deficiency in the presence of severe obesity (e.g. Prader–Willi syndrome)GH deficiency after treatment for malignancyDiabetes mellitusHypothyroidismGH insufficiencyConstitutional delay of growth and adolescence (normal IGFBP-3)Sex